Finance

Lists
Outlook: 25.0% bullish·6.2% bearish
Go to analysis
BCAX:NASDAQ
Bicara Therapeutics Inc
$10.02
-0.89%
(-0.090) 1D
$10.02
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCAX...
Open
$9.96
High
$10.14
Low
$9.71
Mkt. cap
665.20M
Avg. vol.
1.78M
Volume
1.52M
52-wk high
$30.99
52-wk low
$7.87
EPS
-$3.46
Shares outstanding
66.39M
No. of employees
103
Open
$9.96
High
$10.14
Low
$9.71
Mkt. cap
665.20M
Avg. vol.
1.78M
Volume
1.52M
52-wk high
$30.99
52-wk low
$7.87
EPS
-$3.46
Shares outstanding
66.39M
No. of employees
103
News stories
From web sources and news partners
About Bicara Therapeutics Inc
CEO-
Employees103
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebicara.com
Analyst ratings
Based on 9 analysts giving stock ratings to BCAX in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BCAX in the last 3 months.
Highest
Current $10.02
$43.00 (+329.14%)
Average
$31.78 (+217.17%)
Lowest
$8.00 (-20.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Maintained
$36.00
+259.3%
11/11/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$43.00
+329.1%
11/10/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$30.00
+199.4%
11/10/2026
David Lebowitz
BMO Capital
Buy
Maintained
$35.00
+249.3%
11/10/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$37.00
+269.3%
11/09/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$34.00
+239.3%
11/09/2026
Boris Peaker
JonesTrading
Buy
Maintained
$30.00
+199.4%
11/09/2026
Richard Law CFA
Goldman Sachs
Sell
Downgraded
$8.00
-20.2%
10/29/2026
Unknown Analyst
Wedbush
Buy
Maintained
$33.00
+229.3%
10/26/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$41.00
+309.2%
10/20/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$35.00
+249.3%
08/18/2026
Joseph Catanzaro
Mizuho Securities
Hold
Maintained
$20.00
+99.6%
08/13/2026
Rajan Sharma
Goldman Sachs
Hold
Reiterated
$20.00
+99.6%
08/11/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$23.00
+129.5%
08/12/2026
Bradley Canino
Guggenheim
Buy
Maintained
$42.00
+319.2%
05/26/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$30.00
+199.4%
04/06/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$31.00
+209.4%
01/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
32.99M
47.50M
45.77M
56.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.13M
12.74M
14.18M
19.24M
Operating expense
41.12M
60.24M
59.95M
75.71M
Total operating expenses
41.12M
60.24M
59.95M
75.71M
Operating income
-41.12M
-60.24M
-59.95M
-75.71M
Other non operating income
-
-
-
-
EBT including unusual items
-37.33M
-56.16M
-55.38M
-71.20M
EBT excluding unusual items
-37.33M
-56.16M
-55.38M
-71.20M
Income tax expense
53.00K
52.00K
61.00K
54.00K
Effective tax rate
-0.14%
-0.09%
-0.11%
-0.08%
Other operating expenses
-
-
-
-
Net income
-37.39M
-56.21M
-55.44M
-71.25M
Net profit margin
-
-
-
-
Earnings per share
-0.68
-0.93
-0.82
-1.04
Interest and investment income
3.79M
4.08M
4.58M
4.52M
Interest expense
-
-
-
-
Net interest expenses
3.79M
4.08M
4.58M
4.52M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.08M
-60.20M
-59.91M
-75.65M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps